8-K: Mangoceuticals, Inc. Executes Multiple Agreements to Expand Business Operations

Mangoceuticals, Inc. has entered into several agreements including assignment of contracts to a subsidiary, a service agreement, and a distribution agreement to expand its business operations.

Summary

• Mangoceuticals, Inc. has entered into an agreement to assign its rights and obligations under existing agreements with Epiq Scripts, LLC to its wholly-owned subsidiary, Mango & Peaches Corp.
• The company has also entered into a service agreement with LT Global Practice Management for virtual professionals.
• Additionally, Mangoceuticals has secured a master distribution agreement with Propre Energie Inc. to license intellectual property for plant-based skin brightening products.
• A previous debt of $500,000 owed to Barstool Sports, Inc. and purchased by MAAB Global Ltd. has been amended to allow MAAB to convert the debt into shares of Mangoceuticals common stock at $1.50 per share.
• The company will issue 650,000 restricted shares of common stock to Propre Energie Inc. and pay 1% of gross sales revenue from the licensed products.

Sentiment

Score: 6

Explanation: The document indicates strategic moves for growth, but also includes potential dilution and related party transactions, leading to a moderately positive sentiment.

Positives

• The assignment of agreements to Mango & Peaches Corp. may streamline operations.
• The service agreement with LT Global Practice Management provides access to virtual professionals, potentially reducing overhead costs.
• The master distribution agreement with Propre Energie Inc. expands the company's product portfolio into the skin care market.
• The debt conversion option with MAAB Global Ltd. could reduce the company's debt burden and provide additional capital.

Negatives

• The company is issuing a significant number of shares (650,000) to Propre Energie Inc., which could dilute existing shareholders.
• The 1% royalty on gross sales to Propre Energie Inc. will reduce profit margins on Dermytol products.
• The debt conversion price of $1.50 per share may be dilutive if the current share price is lower.
• The company is entering into agreements with entities owned by or related to the CEO, which could raise conflict of interest concerns.

Risks

• The success of the Dermytol product line is dependent on market acceptance and effective marketing.
• The company's reliance on related parties for services and intellectual property could pose governance risks.
• The potential conversion of debt into equity could dilute existing shareholders.
• The company's ability to manage the new agreements and integrate the new products into its existing operations is uncertain.

Future Outlook

The company is expanding its business operations through strategic agreements, including entering the skin care market with the Dermytol brand. The company is also working to reduce its debt burden through a debt conversion option.

Management Comments

• The company, with the approval of the disinterested members of the Board of Directors and the Companys Audit Committee, made up of independent members of the Board of Directors, entered into two Assignment, Assumption and Novation Agreements with Epiq Scripts, LLC.
• The company, with the approval of the disinterested members of the Board of Directors and the Companys Audit Committee, made up of independent members of the Board of Directors, entered into an LT Global Practice Management Service Agreement with LT Global.

Industry Context

The company is diversifying its product portfolio by entering the skin care market, which is a growing sector. The company is also leveraging its existing infrastructure to expand its business operations.

Comparison to Industry Standards

• The use of virtual professionals is becoming increasingly common in various industries, including healthcare and pharmaceuticals, as companies seek to reduce costs and improve efficiency. Companies like Upwork and TaskUs provide similar services.
• Licensing intellectual property for product development is a common practice in the pharmaceutical and cosmetic industries. Companies like Johnson & Johnson and L'Oréal often engage in such agreements.
• Debt conversion is a common method for companies to reduce debt and raise capital. Many companies, particularly in the tech and biotech sectors, have used this method.
• The royalty rate of 1% on gross sales is relatively low compared to some licensing agreements, which can range from 5% to 20% or more, depending on the industry and the value of the intellectual property.

Related Party Transactions

• The Epiq Scripts Assignments were entered into with Epiq Scripts, LLC, which is 51% owned by Jacob Cohen, the company's CEO and Chairman.
• The LT Service Agreement was entered into with LT Global Practice Management, which is owned by the wife of Mr. Cohen.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be impacted by the addition of virtual professionals.
• Customers will have access to new skin care products.
• Suppliers will be impacted by the new distribution agreement.
• Creditors may be impacted by the debt conversion option.

Next Steps

• Mango & Peaches Corp. will assume the obligations of the agreements with Epiq Scripts, LLC.
• LT Global Practice Management will begin providing virtual professionals to the company.
• Mangoceuticals will begin marketing and distributing Dermytol products.
• MAAB Global Ltd. may exercise its option to convert debt into equity.
• The company will need to integrate the new products and services into its existing operations.

Key Dates

Keywords

distribution agreement, intellectual property, virtual professionals, debt conversion, skin brightening, pharmaceuticals, master services agreement, consulting agreement, indemnification, licensing